| Literature DB >> 29706566 |
Xuebo Pan1, Yihui Shao2, Fan Wu3, Yuan Wang2, Rongrong Xiong4, Jujia Zheng4, Haishan Tian4, Baile Wang5, Yanfang Wang3, Yi Zhang4, Zongsheng Han6, Aijuan Qu7, Haixia Xu8, Aihua Lu9, Tianxin Yang10, Xiaokun Li11, Aimin Xu5, Jie Du2, Zhuofeng Lin12.
Abstract
Fibroblast growth factor 21 (FGF21) is a metabolic hormone with pleiotropic effects on glucose and lipid metabolism and insulin sensitivity. However, the role of FGF21 in hypertension remains elusive. Here we show that FGF21 deficiency significantly exacerbates angiotensin II-induced hypertension and vascular dysfunction, whereas such negative effects are reversed by replenishment of FGF21. Mechanistically, FGF21 acts on adipocytes and renal cells to promote induction of angiotensin-converting enzyme 2 (ACE2), which in turn converts angiotensin II to angiotensin-(1-7), then inhibits hypertension and reverses vascular damage. In addition, ACE2 deficiency strikingly abrogates these beneficial effects of FGF21 in mice, including alleviation of angiotensin II-associated hypertension and vascular damage. Otherwise, pharmaceutical inhibition of angiotensin-(1-7) attenuates the protective effect of FGF21 on angiotensin II-induced vascular dysfunction, but not on hypertension. Thus, FGF21 protects against angiotensin II-induced hypertension and vascular impairment by activation of the ACE2/angiotensin-(1-7) axis via fine-tuning the multi-organ crosstalk between liver, adipose tissue, kidney, and blood vessels.Entities:
Keywords: ACE2; FGF21; angiotensin II; angiotensin-(1–7); hypertension
Mesh:
Substances:
Year: 2018 PMID: 29706566 DOI: 10.1016/j.cmet.2018.04.002
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287